Thomas Rachel
Lung Cancer Nurse Specialist, Palliative Care Department, Guy's Hospital, Guy's and St Thomas' NHS Foundation Trust.
Br J Nurs. 2016 Sep 8;25(16):S12-7. doi: 10.12968/bjon.2016.25.S12.
Patients diagnosed with advanced non-small-cell lung cancer (NSCLC) (either squamous or non-squamous) have previously had limited treatment options after progression on chemotherapy. With the emergence of new drugs, particularly in the immuno-oncology setting, this is now changing. Recent clinical trial evidence demonstrates that compared with docetaxel, patients who received nivolumab had better overall survival and also significantly fewer grade 3-4 adverse events. This article reviews the clinical trial data for nivolumab and provides an overview of how this drug works. The adverse event profile of nivolumab is assessed and compared to that of docetaxel. The important role that nurses can play in supporting patients on nivolumab is also discussed.
被诊断为晚期非小细胞肺癌（NSCLC）（鳞状或非鳞状）的患者，在化疗进展后，以往的治疗选择有限。随着新药的出现，尤其是在免疫肿瘤学领域，这种情况正在改变。最近的临床试验证据表明，与多西他赛相比，接受纳武单抗治疗的患者总生存期更长，3-4级不良事件也显著更少。本文回顾了纳武单抗的临床试验数据，并概述了该药物的作用机制。评估了纳武单抗的不良事件情况，并与多西他赛进行了比较。还讨论了护士在支持使用纳武单抗的患者方面可发挥的重要作用。
